Market Overview - Last week, the A-share pharmaceutical and biotechnology index fell by 0.14%, underperforming the CSI 300 index by 0.14 percentage points, while outperforming the ChiNext index by 1.39 percentage points, ranking 22nd among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index also declined by 1.77%, outperforming the Hang Seng Index by 0.19 percentage points [4] R&D Progress - Last week, SSGJ-608 NDA application from 3SBio was newly undertaken; the 24-valent pneumococcal polysaccharide conjugate vaccine from CanSino and SYH2069 from CSPC were also newly undertaken for clinical application [5] - Hengrui Medicine's 9531 is in Phase III clinical trials; HRS-7249 is in Phase II clinical trials; and CanSino's CM383 is in Phase I clinical trials [5] Investment Insights - The recent rebranding of Ant Group's AI health application "AQ" to "Antifufu" has led to a surge in downloads, reaching the top 3 in the Apple App Store and surpassing 15 million monthly active users, making it the leading AI health management app in China [6] - Antifufu integrates over 500 national-level academicians and renowned doctors into its "AI avatar" service, transforming scarce expert resources into 24/7 accessible services [6] - This product iteration shifts the traditional low-frequency medical visits into high-frequency health management, creating a digital closed loop from consultation, medication purchase to insurance claims, thus enhancing the "medical + pharmaceutical + insurance" integration [6] Future Investment Strategy - With the changing macroeconomic and policy landscape, future investments in the pharmaceutical sector should increasingly focus on the intrinsic clinical value of pharmaceuticals, addressing clinical needs of patients [7] - Both domestic medical insurance policies and global expansion strategies are placing higher premiums on clinical value [7]

公司净利润呈下滑态势，上半年亏损超4亿元 根据灼识咨询的资料，以2024年收入计，吉因加科技在中国精准诊断解决方案行业排名第三。在药物研 发赋能领域，公司提供围绕伴随诊断构建的全生命周期服务。 业绩方面，吉因加科技近年营收波动较大，净利润呈下滑态势。2022年、2023年、2024年、2025年上半 年，吉因加科技收入分别为18.15亿元、4.73亿元、5.57亿元、2.85亿元；期内净利润分别为3.72亿元、 5412.70万元、-4.24亿元、-4.14亿元。 招股书显示，吉因加科技是中国领先的精准医疗公司，将AI能力深度嵌入生物标志物价值链的各个核 心环节。基于自主研发的多组学平台，结合基础大模型与智能体AI，吉因加科技构建出了从多组学生 物标志物及靶点的发现、验证、产品开发到商业化落地的全链条能力。由此，公司面向医院、制药及生 物技术公司、医学研究机构等，提供三大解决方案：精准诊断、药物研发赋能以及临床科研与转化。 吉因加科技的三大业务线协同互补。截至2025年6月，吉因加科技已服务1000余家医院(涵盖中国百强医 院中的30家)，并与200余家制药企业及500余家临床研究机构建立合作。 【深圳商报讯 ...

12月22日，市场高开高走，三大指数集体反弹，创业板指涨超2%。沪深两市成交额1.86万亿，较上一个交易日放量1360亿。 沪指站上3900点整数关和60日均线这一牛熊分界线，创业板指也强势反包收复10日均线。截至收盘，沪指涨0.69%，深成指 涨1.47%，创业板指涨2.23%。 | 大涨板块 | 251222 (周1) | 251219 (周5) | 251218 (周4) | 251217 (周3) | 251216 (周2) | | --- | --- | --- | --- | --- | --- | | 1 | 海南自由贸易港23 | 大消费17 | 玩天15 | 液冷服务器14 | 无人驾驶10 | | 2 | 光通信12 | 海南自由贸易港7 | AI医疗11 | 光通信16 | 大消费16 | | 3 | 国产芯片17 | 核聚变8 | 大消费22 | 锂电池10 | 数字人民币4 | | র্ব | 民爆2 | 无人驾驶11 | IP经济/谷子经济3 | PCB板9 | 航天12 | | ર | 师天10 | 师天15 | 光通信3 | 大消费8 | 智能电网2 | | 6 | ST股23 ...

2025深圳 国际高性能医疗器械展暨创新医药展现场。主办方供图 加拿大皇家学院院士李仁科表示，十余年前国内医疗器械以模仿、跟随为主，当前已实现从模仿到自主 创新的突破，拥有自主新产品、新专利，整体发展水平与世界并驾齐驱，发展成果令人震撼。 他同时指出，未来医疗器械不应是"硬邦邦"的传统器械，而是整合生物工程、细胞技术、AI、大数据等 多领域技术，突破传统器械的局限，向智能化、个体化、"活性化"发展，实现与人体深度融合，真正聚 焦解决人体健康与疾病问题。 来源：中国青年报客户端 中国青年报客户端讯（中青报·中青网记者 刘芳）12月20日，2025深圳国际高性能医疗器械展暨创新医 药展（以下简称"展会"）在深圳落幕，为期3天的展会汇聚全球300余家企业，集中展示千余件创新产 品，同步发布系列产业重磅成果与多项医工合作项目，全方位呈现我国药械产业从"技术追赶"向"创新 引领"跨越的发展态势。 展会核心亮点之一是系列年度创新成果的集中亮相。由国家高性能医疗器械创新中心发起的"2025年度 医疗器械行业创新生态洞察评估"结果正式揭晓，涵盖企业、产品、医院、高校等带来的11项评估结 果。其中"新锐企业100强"覆盖高端医 ...

周五前有股指期货各大空头集体加仓，后有平潭带动高位股尾盘跳水，周一行情到底怎么走？如果还不 知道下周该怎么交易的请务必听我说完，首先我们来一下股指期货的多空持仓情况，很明显三大指数合 约的净空头都是加仓为主，中信更是直接加仓1953张，所以数据告诉我们机构资金开始逐步转向防御， 这点也很好的解释了为什么周五尾盘平潭跳水以及防御题材上位了，不过需要注意的是，周五晚间老美 科技股集体反弹，明天开盘应该问题不大，倘若高开后未明显下跌，则说明这里依然有承接，行情还将 以震荡为主，否则大盘存在调整风险。 说完大盘再来说说情绪，周四视频的最后，我们特地提醒大家，周五对高位股是个坎，几个核心票仍需 经过市场检验，结果平潭在尾盘的时候就飞流直下，平潭是这轮嵌套周期的龙头，正所谓龙头不A杀， 所以这里先不用去担心它会一跌到底，快则周一慢则周二就能看到平潭止跌，但是这个下跌却起到了吹 哨人的作用，不排除接下来的高位抱团有点想要瓦解的意思，因此对于高位股来说，即便还能新高，其 风险也会逐步大于机会，这样看来或许机构围绕易中天抱团这件事还能继续下去。 板块方面近期呈现几个特点，首先就是消息面占据主导，无论是核电还是智驾，又或者是光模 ...

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector [4][5]. Core Insights - The report emphasizes the activation of "medical insurance" through AI in healthcare, suggesting a focus on investment opportunities in related sectors such as home medical devices, offline health check-ups, and pharmaceutical retail [2][21][23]. - The report highlights the importance of clinical value in the pharmaceutical sector, advocating for investments in innovative drug chains and medical devices, particularly in light of evolving domestic and international policies [3][26][27]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index fell by 0.14%, underperforming the CSI 300 index by 0.14 percentage points, while outperforming the ChiNext index by 1.39 percentage points, ranking 22nd among 31 sub-industries [1][10][16]. - The Hong Kong Hang Seng Healthcare Index decreased by 1.77%, outperforming the Hang Seng Index by 0.19 percentage points [1][10]. R&D Progress - Recent developments include the NDA application for SSGJ-608 by Sanofi, clinical application advancements for vaccines by CanSino and Shiyao Group, and ongoing clinical trials for various drugs by Heng Rui and CanOya [1][31]. Investment Strategy - The report suggests focusing on three categories of companies: 1. AI + Home Medical Devices, recommending companies like Yuyue Medical and Sinocare [23][25]. 2. AI + Offline Health Check-ups, with a focus on Meinian Health, which has significant data resources for AI model calibration [23][25]. 3. AI + Pharmaceutical Retail, highlighting Alibaba Health and Shuyu Pingmin as key players [23][25]. Key Company Earnings Forecast and Valuation - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for several companies, recommending "Buy" for companies like Innovent Biologics, Yifan Biologics, and Mindray Medical [4][28]. Important Company Announcements - Recent announcements include various clinical trial approvals and strategic partnerships among key players in the pharmaceutical sector, indicating ongoing innovation and development [30][31]. Financial Data Updates - Basic medical insurance revenue reached 2,108.6 billion yuan in the first nine months of 2025, with a monthly income of 227.6 billion yuan in September, reflecting a 15.9% month-on-month increase [34]. - The pharmaceutical manufacturing industry reported a year-on-year revenue decline of 2.90% for the first ten months of 2025, indicating challenges in the sector [49]. Regulatory and Market Trends - The report notes a structural shift in domestic policies favoring innovative drugs and highlights the increasing global demand for pharmaceuticals driven by aging populations [27][26].

转自：新华财经 新华财经北京12月22日电 （胡晨曦）A股三大指数12月22日早间集体高开，随后全天震荡走强，沪指重 返3900点上方，创业板指大涨超2%。沪深两市成交额1.86万亿，较上一个交易日放量1360亿。盘面 上，海南板块集体爆发，海南矿业、海南橡胶等近20股涨停；算力硬件概念表现活跃，新易盛再创历史 新高，亨通光电、长飞光纤等涨停；商业航天概念反复走强，神剑股份回封涨停。下跌方面，AI医疗 概念下挫，华人健康跌超9%；影视院线概念下挫，博纳影业跌停。 小米17 Ultra定档12月25日发布 巨丰投顾：周一市场震荡反弹，海南自贸区板块涨幅居前。从目前趋势看，市场整体趋势依然向上，多 数板块在60日均线位置获得支撑，并开启反弹行情；部分热门股创出历史新高。投资者可重点关注前期 热门行业龙头回调后的低吸机会。从长期趋势来看，在政策刺激下，A股与经济有望同步出现向上的拐 点。具体投资方向上，中线建议关注维持高景气度的半导体、消费电子、人工智能、机器人、商业航天 等领域的增量机会；对于风险偏好较低的投资者，可逢低关注中证A500ETF、沪深300ETF等宽基基 金。 中信证券：截至2025年12月中旬Sp ...

东方财富 12月22日，A股三大指数高开高走。截至午间收盘，上证指数涨0.64%，报3915.20点；深证成指涨1.36%，报13318.80点；创业板指涨1.80%，报3178.51点。 全市半日成交额1.20万亿，超3400只个股上涨。 从板块来看，海南自贸概念集体爆发，海汽集团、海南瑞泽等近20股涨停。商业航天概念反复走强，神剑股份、北斗星通涨停。算力硬件概念表现活 跃，"易中天"光模块三巨头集体上涨。半导体设备股拉升，拓荆科技等多股创历史新高。 东方财富 下跌方面，AI医疗概念震荡回落，华人健康大跌。板块方面，海南自贸区、贵金属、算力硬件等板块涨幅居前，医药商业、影视院线、银行等板块跌幅居 前。 ...

晨会纪要（2025/12/22） 编辑人 022-28451618 SAC NO：S1150511010016 cuijian@bhzq.com 崔健 渤海证券研究所晨会纪要（2025.12.22） 宏观及策略研究 数据密集披露，等待政策反应——宏观经济周报 固定收益研究 短债利率下行，超长债波动幅度较大——利率债周报 公司研究 全球人造草坪龙头，海外产能扩张稳固领先优势——共创草坪（605099）公 司深度报告 请务必阅读正文之后的声明 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 7 晨会纪要（2025/12/22） 行业研究 证 全国医疗保障工作会议召开，部署 2026 年重点工作——医药生物行业周报 券 研 究 报 告 晨 会 纪 要 宏观及策略研究 数据密集披露，等待政策反应——宏观经济周报 周 喜（证券分析师，SAC NO：S1150511010017） 宋亦威（证券分析师，SAC NO：S1150514080001） 严佩佩（证券分析师，SAC NO：S1150520110001） 靳沛芃（研究助理，SAC NO：S1150124030005） 1、外围环境而言 美国方面，10 月和 ...

Important Market News - China successfully launched the communication technology test satellite No. 23 using the Long March 5 rocket, marking the 618th flight of the Long March series [1] Industry Insights - Google has announced the "Project Suncatcher" plan in collaboration with Planet to launch a cluster of 81 satellites, aiming to create a prototype space data center. The project features three breakthroughs: a distributed collaborative architecture for high-frequency communication between satellites, a fully solar-powered design with energy consumption at only 1/5 of ground data centers, and dedicated edge computing modules for real-time data processing in orbit [2] - The satellite internet sector is becoming a new frontier in global technology competition, with the satellite communication industry expected to exceed 200-400 billion yuan by 2030, with an annual compound growth rate of 10%-28%. The industry is transitioning from "concept validation" to "scale application," forming a new communication pattern of "integrated space and ground, interconnected everything" [3] - A fully 3D-printed turbofan engine developed by a consortium including the Chinese Academy of Sciences has completed ground testing. This engine simplifies the traditional multi-part assembly into an integrated component, representing a significant innovation in manufacturing [4] - The 3D-printed turbofan engine reduces the number of core components by over 40% and the structural weight by 25%, enhancing the thrust-to-weight ratio and paving the way for lightweight, high-performance aviation power equipment [4] - Ant Group's AI health application "Antifufu" has seen a surge in downloads, ranking second on Apple's free app chart. The app was upgraded to enhance health companionship, Q&A, and services, leveraging Ant Group's extensive healthcare resources [5] - The AI healthcare sector in China is projected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, with a notable compound annual growth rate. Key growth areas include AI medical imaging and AI pharmaceuticals [5]